Investment
Features
FeesSafety
Academy
More
Pluang+

Bitcoin trades near $82,769 as 10-year Treasury yield drops, easing borrowing costs for tech investments.

Market News
19 Oct 2026
Tokenpost
View Source
Neutral
Bitcoin trades near $82,769 as 10-year Treasury yield drops, easing borrowing costs for tech investments.

Bitcoin traded at $82,769 ahead of the U.S. stock market open, coinciding with a drop in the 10-year Treasury yield from 5.3% to 5.08%. This yield decline helped lift S&P 500 futures by 0.47% after a recent dip. Lower Treasury yields reduce borrowing costs, which is significant for companies investing in artificial intelligence, as higher yields raise the cost of capital. Although the recent drop doesn't change the overall cost of capital for large tech firms, it highlights the ongoing impact of bond yields on financing conditions as markets open.

Bitcoin traded at $82,769 as the 10-year Treasury yield eased to 5.08%, providing context for market conditions. For readers following cryptocurrency, here is Pluang's market snapshot as of Oct 19, 2026 18:21 WIB: out of 50 major cryptocurrencies, 23 rose and 25 fell. Notable movers include ATOM (Cosmos) at Rp31.176 with a 2.78% gain and a typical hold time of 61 days, FTM (Fantom) at Rp11.382 down 2.05%, and THETA (Theta Network) at Rp3.369 down 2.04%.

More News

Lexeo Therapeutics to host event on clinical measures in PKP2 arrhythmogenic cardiomyopathy

Lexeo Therapeutics to host event on clinical measures in PKP2 arrhythmogenic cardiomyopathy

Lexeo Therapeutics announced an educational event on October 21, 2026, focusing on clinical endpoints and outcome measures in PKP2 arrhythmogenic cardiomyopathy (PKP2-ACM). The event will feature discussions by Lexeo's Chief Medical Officer and a lea...

Others
Neutral
1 hour ago
EyePoint's DURAVYU misses primary endpoint in wet AMD trial but shows reduced treatment burden and safety.

EyePoint's DURAVYU misses primary endpoint in wet AMD trial but shows reduced treatment burden and safety.

EyePoint announced that its DURAVYU treatment for wet age-related macular degeneration (wet AMD) did not meet the primary goal of matching the visual improvement of the standard aflibercept treatment in the LUCIA Phase 3 trial. However, DURAVYU demon...

Company Fundamentals
Neutral
1 hour ago
Marker Therapeutics wins $2.6M FDA grant to advance MT-601 therapy for pancreatic cancer.

Marker Therapeutics wins $2.6M FDA grant to advance MT-601 therapy for pancreatic cancer.

Marker Therapeutics has been awarded a $2.6 million grant from the FDA's Orphan Products Clinical Trials program to support a Phase 1 study of its MT-601 multi-antigen recognizing T cell therapy for locally advanced unresectable pancreatic cancer. Th...

Market News
Bullish
1 hour ago
Agility Robotics appoints Mark Vale as audit committee chair ahead of public listing.

Agility Robotics appoints Mark Vale as audit committee chair ahead of public listing.

Agility Robotics announced that Mark Vale, former UPS president and current CEO of Transportation Insight, will join its board and chair the audit committee after its merger with Churchill Capital Corp XI. Vale's extensive experience in global logist...

Company Fundamentals
Bullish
1 hour ago
JazzCash wins Silver Award for innovation in InsurTech at Money20/20 USA 2026

JazzCash wins Silver Award for innovation in InsurTech at Money20/20 USA 2026

JazzCash, Pakistan's leading digital financial services platform, won the Silver Award in the Banking – InsurTech category at Money20/20 USA 2026 for its health-protection platform Sehat+. This platform provides affordable health insurance to Pakista...

Market News
Bullish
1 hour ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App